

References: Influenza Neuraminidase Assay with NA-Star® Chemiluminescent Substrate/NA-Star® Influenza Neuraminidase Inhibitor Resistance Detection Kit

- Buxton, RC, B Edwards, RR Juo, JC Voyta, M Tisdale and RC Bethell (2000). Development of a sensitive chemiluminescent neuraminidase assay for the determination of influenza virus susceptibility to Zanamivir. *Anal Biochem* 280:291-300.
- Boivin, G and N Goyette (2002). Susceptibility of recent Canadian influenza A and B virus isolates to different neuraminidase inhibitors. *Antiviral Research* 54:143-147.
- Aymard, M, O Ferraris, L Gerentes, J Jolly and N Kessler (2003). Neuraminidase assays. *Developmental Biology* 115:75-83.
- McKimm-Breschkin, J, T Trivedi, A Hampson, A Hay, A Klimov, M Tashiro, F Hayden and M Zambon (2003). Neuraminidase sequence analysis and susceptibilities of influenza virus clinical isolates to Zanamivir and Oseltamivir. *Antimicrobial Agents and Chemotherapy* 47(7):2264-2272.
- Mungall, BA, X Xu and A Klimov (2003). Assaying susceptibility of avian and other influenza A viruses to Zanamivir: Comparisons of fluorescent and chemiluminescent neuraminidase assays. *Avian Diseases* 47:1141-1144.
- Wetherall, NT, T Trivedi, J Zeller, C Hodges-Savola, JL McKimm-Breschkin, M Zambon and FG Hayden (2003). Evaluation of neuraminidase enzyme assays using different substrates to measure susceptibility of influenza virus clinical isolates to neuraminidase inhibitors: Report of the Neuraminidase Inhibitor Susceptibility Network. *J Clin Microbiol* 41(2):742-750.
- Mungall BA, X Xu and A Klimov (2004). Surveillance of influenza isolates for susceptibility to neuraminidase inhibitors during the 2000-2002 influenza seasons. *Virus Research* 103:195-197.
- Hurt, AC, JL McKimm-Breschkin, M McDonald, IG Barr, N Komadina and AW Hampson (2004). Identification of a human influenza type B strain with reduced sensitivity to neuraminidase inhibitor drugs. *Virus Research* 103:205-211.
- Jackson, D, W Barclay and T Zurcher (2005). Characterization of recombinant influenza B viruses with key neuraminidase inhibitor resistance mutations. *J Antimicrobial Chemotherapy* 55(2):162-169.
- The World Health Organization Global Influenza Program Surveillance Network (2005). Evolution of H5N1 avian influenza viruses in Asia. *Emerging Infectious Diseases* 11(10):1515-1521.
- Monto, AS, JL McKimm-Breschkin, C Macken, AW Hampson, A Hay, A Klimov, M Tashiro, RG Webster, M Aymard, FG Hayden and M Zambon (2006). Detection of influenza viruses resistant to neuraminidase inhibitors in global surveillance during the first 3 years of their use. *Antimicrobial Agents and Chemotherapy* 50(7):2395-2402.
- Zurcher, T, PJ Yates, J Daly, A Sahasrabudhe, M Walters, L Dash, M Tisdale and JL McKimm-Breschkin (2006). Mutations conferring zanamivir resistance in human influenza virus N2 neuraminidases compromise virus fitness and are not stably maintained *in vitro*. *J Antimicrobial Chemotherapy* 58:723-732.
- Bright, RA, DM Carter, S Daniluk, FR Toapanta, A Ahmad, V Gavrilov, M Massare, P Pushko, N Mytle, T Rowe, G Smith and TM Ross (2007). Influenza virus-like particles elicit broader immune responses than whole virion inactivated influenza virus or recombinant hemagglutinin. *Vaccine* 25:3871-3878.
- Sheu, TG, VM Deyde, M Okomo-Adhiambo, RJ Garten, X Xu, RA Bright, EN Butler, TR Wallis, AI Klimov and LV Gubareva (2008). Surveillance for neuraminidase inhibitor resistance among human influenza A and B viruses circulating worldwide from 2004 to 2008. *Antimicrobial Agents and Chemotherapy* 52(9):3284-3292.
- Le, MTQ, HFL Wertheim, HD Nguyen, W Taylor, PVM Hoang, et al. (2008). Influenza A H5N1 clade 2.3.4 virus with a different antiviral susceptibility profile replaced clade 1 virus in humans in northern Vietnam. *PLoS ONE* 3(10):e3339. doi:10.1371/journal.pone.0003339.